Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA3 | P07451 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | CA6 | P23280 | 1/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL582871 | 0.91 | TMEM97 (0.57) | TMEM97SIGMAR1HTTTSHRALDH1A1 | |
| SCHEMBL26838419 | 0.88 | TMEM97 (0.59) | TMEM97SIGMAR1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL21210764 | 0.85 | HTT (0.58) | HTTTSHRSMN1; SMN2NPC1LMNA | |
| SCHEMBL3346723 | 0.84 | DGAT1 (0.54) | TMEM97SIGMAR1TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL2921979 | 0.84 | TMEM97 (0.56) | TMEM97SIGMAR1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL12121122 | 0.84 | HTT (0.57) | HTTTSHRALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL360641 | 0.84 | HTT (0.57) | HTTTSHRALDH1A1SMN1; SMN2CA12 | |
| SCHEMBL4510569 | 0.83 | TMEM97 (0.58) | TMEM97SIGMAR1ALDH1A1SMN1; SMN2CA12 | |
| SCHEMBL24100547 | 0.82 | HPGD (0.66) | TMEM97SIGMAR1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL2926409 | 0.81 | CYP1A2 (0.67) | TMEM97SIGMAR1HTTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9126962-B2 | Substituted phenylcarbamoyl alkylamino arene compounds and N,N′-BIS-arylurea compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-9023869-B2 | Substituted phenylcarbamoyl alkylamino arene compounds and N,N'-BIS-arylurea compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20150031726-A1 | Substituted Phenylcarbamoyl Alkylamino Arene Compounds and N,N'-BIS-Arylurea Compounds | MEDIVATION TECHNOLOGIES LLC | 2015-01-29 | — | — | US | disclosed |
| US-8710086-B2 | Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods of use thereof | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20130079372-A1 | Substituted Phenylcarbamoyl Alkylamino Arene Compounds and N,N'-BIS-Arylurea Compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| EP-2485804-A1 | SUBSTITUTED PHENYLCARBAMOYL ALKYLAMINO ARENE COMPOUNDS AND N,N'-BIS-ARYLUREA COMPOUNDS | Medivation Prostate Therapeutics, Inc. (US) | 2012-08-15 | — | — | EP | disclosed |
| US-20120184580-A1 | SUBSTITUTED DI-ARYLHYDANTOIN AND DI-ARYLTHIOHYDANTOIN COMPOUNDS AND METHODS OF USE THEREOF | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| EP-2416657-A1 | SUBSTITUTED DI-ARYLHYDANTOIN AND DI-ARYLTHIOHYDANTOIN COMPOUNDS AND METHODS FOR USE THEREOF | Medivation Prostate Therapeutics, Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| WO-2011044327-A1 | SUBSTITUTED PHENYLCARBAMOYL ALKYLAMINO ARENE COMPOUNDS AND N,N'-BIS-ARYLUREA COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2010118354-A1 | SUBSTITUTED DI-ARYLHYDANTOIN AND DI-ARYLTHIOHYDANTOIN COMPOUNDS AND METHODS FOR USE THEREOF | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184580-A1 | SUBSTITUTED DI-ARYLHYDANTOIN AND DI-ARYLTHIOHYDANTOIN COMPOUNDS AND METHODS OF USE THEREOF | AR, BRDT, AADAC | TMEM97 4054/4885SIGMAR1 4281/4885HTT 1889/4885 |
| US-20130079372-A1 | Substituted Phenylcarbamoyl Alkylamino Arene Compounds and N,N'-BIS-Arylurea Compounds | AR, NAT1, NCOA1 | TMEM97 935/4885SIGMAR1 530/4885HTT 398/4885 |
| US-20150031726-A1 | Substituted Phenylcarbamoyl Alkylamino Arene Compounds and N,N'-BIS-Arylurea Compounds | AR, NAT1, NCOA1 | TMEM97 935/4885SIGMAR1 530/4885HTT 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.